At the European Society of Cardiology (ESC) Congress 2026, investigators presented the TARGET-CTCA Trial, examining whether Coronary CT Angiography (CCTA) improves outcomes in patients presenting with acute chest pain after myocardial infarction (MI) has already been excluded. The results challenge a long-standing assumption that identifying more coronary artery disease automatically translates into better patient outcomes.
Why This Study Matters
Modern emergency departments increasingly rely on high-sensitivity troponin testing to rapidly evaluate patients with suspected acute coronary syndrome (ACS). Many patients ultimately have MI ruled out but remain at intermediate cardiovascular risk due to modest troponin elevations or clinical risk factors.
Current U.S. chest pain guidelines support selective use of CCTA in such patients. However, whether imaging-guided management reduces future cardiovascular events has remained uncertain.
TARGET-CTCA Trial Design
The study enrolled 3,170 patients presenting to emergency departments across 14 hospitals in the United Kingdom.
Patient Characteristics
- Median age: 61 years
- Women: 30.2%
- Prior MI: 17.5%
- History of angina: 15.1%
- Nearly 90% presented with chest discomfort
Patients were randomized to either:
- CCTA-guided management
- Standard care
The median follow-up period was approximately three years.
What Did CCTA Reveal?
Among patients undergoing Coronary CT Angiography:
- 42.5% had non-obstructive coronary artery disease
- 22.6% had obstructive coronary artery disease
- More patients received statin therapy
- More patients received antiplatelet therapy
- Rates of percutaneous coronary intervention (PCI) were modestly higher
These findings demonstrated that CCTA successfully identified previously undiagnosed atherosclerotic coronary artery disease and altered medical management.
The Primary Outcome
The primary endpoint was a composite of:
- Myocardial Infarction
- Death from a Cardiac Cause
After approximately three years:
| Group | Primary Event Rate |
|---|---|
| CCTA | 7.1% |
| Standard Care | 7.3% |
Despite identifying more coronary disease and increasing preventive treatments, CCTA did not significantly reduce myocardial infarction or cardiac death.
Why Didn't More Imaging Improve Outcomes?
Lead investigator Dr. Nicholas Mills noted that elevated high-sensitivity troponin is not specific for coronary artery disease alone.
Troponin elevations may result from:
- Cardiomyopathy
- Heart Failure
- Chronic Kidney Disease
- Structural Heart Disease
The findings suggest that future adverse events in this population may be driven by factors beyond obstructive coronary disease, limiting the impact of imaging-guided interventions.
Clinical Implications
The TARGET-CTCA Trial provides several important takeaways:
✅ CCTA effectively detects coronary artery disease
✅ Imaging increases use of preventive medical therapy
✅ Routine CCTA after MI exclusion does not reduce future MI or cardiac death
✅ No subgroup demonstrated a clear clinical benefit
✅ Troponin elevation alone should not automatically trigger coronary CTA
For practicing cardiologists, these results support a more selective and individualized approach to imaging rather than routine CT evaluation of every intermediate-risk chest pain patient.
What Comes Next?
Attention now turns to the ongoing FAST-CCTA Trial, which may help identify specific patient populations that benefit from CT-based evaluation.
Researchers are also exploring:
- Artificial intelligence–based plaque analysis
- Advanced plaque characterization
- Coronary inflammation assessment
- Enhanced risk stratification tools
These technologies may ultimately improve identification of high-risk patients beyond traditional stenosis assessment.
Bottom Line
The TARGET-CTCA Trial demonstrated that while Coronary CT Angiography identifies significant coronary artery disease and leads to more aggressive preventive therapy, it does not reduce rates of myocardial infarction or cardiac death after MI has already been ruled out.
For cardiologists managing patients with acute chest pain, the study reinforces an important principle: better diagnosis does not always translate into better outcomes, and careful patient selection remains essential when considering advanced cardiac imaging.
Reference
Lee KK, Wereski R, Lowe D, et al. Targeted Use of Computed Tomographic Coronary Angiography in Acute Chest Pain. New England Journal of Medicine. 2026.
